



June 20, 2023

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 ('Listing Regulations').

We are pleased to enclose a Press Note regarding Lupin Human Welfare and Research Foundation, the CSR arm of the Company, having signed a MoU with the Government of Maharashtra, to address the growing prevalence of Cardiovascular and Chronic Obstructive Pulmonary diseases in Palghar district of Maharashtra.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a

Press Note

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin Signs MoU with Government of Maharashtra to Combat Rising Prevalence of Cardiovascular Diseases and COPD

Collaboration to enhance healthcare services, ensure timely diagnosis, and improve accessibility of healthcare services

Mumbai, June 20, 2023: Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of Lupin Limited, announced today that it has signed a Memorandum of Understanding (MoU) with the Government of Maharashtra to address the growing prevalence of Cardiovascular Diseases (CVD) and Chronic Obstructive Pulmonary Disease (COPD) in the Palghar district of Maharashtra. The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence.

“As a leading healthcare provider, Lupin has consistently championed improved accessibility to high-quality, cost-effective medicines for India’s marginalized and vulnerable communities. Through our collaborative efforts with state governments, we aim to strengthen existing healthcare systems and programs, focus on awareness, and enhancing quality, accessibility, and utilisation of healthcare services,” said **Nilesh Gupta, Managing Director, Lupin.**

The MoU was signed by Dr. Nagnath Mudam, Joint Director (NCD), Directorate of Health Services, Maharashtra and Tushara Shankar, Head of Corporate Social Responsibility, Lupin. This collaborative effort marks a crucial milestone in LHWRF’s “Lives” program, amplifying a commitment to address the growing prevalence of cardiovascular diseases and COPD.

“This collaboration is poised to significantly lower the prevalence of CVDs and COPD in Palghar’s selected blocks. Our unwavering dedication to tackling these health concerns with focused solutions will ensure a lasting impact on the community. By emphasizing preventive measures, early detection, and comprehensive treatment options, we aim to alleviate the disease burden in the district, ultimately enhancing the overall health and well-being of the community,” said **Dr. Nagnath Mudam, Joint Director (NCD), Directorate of Health Services, Maharashtra.**

Tushara Shankar, Head of Corporate Social Responsibility, LHWRF, said, “Maharashtra has witnessed a notable surge in the prevalence of CVDs and COPD. Our partnership with the state government is focused on delivering disease management healthcare services, enabling supportive interventions, and prioritizing preventive measures. By offering a comprehensive solution, our aim is to effectively combat these diseases and provide holistic care to the affected population.”

Press Note

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

To lay a strong foundation, an assessment study was conducted to map existing services, identify challenges in healthcare delivery, and estimate the cost-of-service gaps. The findings were reviewed by the Public Health Department (PHD) and incorporated into Lupin's final program.

The program will be implemented over the next five years, initially focusing on two blocks, Palghar and Dahanu. The primary objectives include raising awareness about the risks associated with CVDs and COPD, highlighting the importance of early screening and diagnosis to prevent complications and decrease mortality rates. The campaign will also promote healthy lifestyles and implement preventive measures, underscoring the significance of early screening, diagnosis and adherence to treatment.

About LHWRF

Lupin Human Welfare & Research Foundation (LHWRF) is the social responsibility arm of Lupin limited, which has been working to positively impact rural landscapes since 1988. During its three-decade history, the foundation has touched over 5000 villages in 23 districts across nine states. The organization has been working to address all aspects of development for underprivileged communities in four thematic areas, namely Economic, Social, Infrastructure Development, and Natural Resource Management. It undertakes economic development activities in the fields of agriculture, animal husbandry, women empowerment, and rural industries. The social anchors include health and education, while infrastructure development and natural resource development have been the key drivers of growth in backward regions where it operates. LHWRF has adopted a new strategic approach to working on Lives (Healthcare) and Livelihoods.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.



Press Note

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

For further information or queries please contact:

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com